NCT01897116 is a Phase 1 clinical trial of Hydroxychloroquine (HCQ) in Melanoma, sponsored by Abramson Cancer Center at Penn Medicine.

Who is sponsoring NCT01897116?

NCT01897116 is sponsored by Abramson Cancer Center at Penn Medicine.

What drugs are being tested in NCT01897116?

Interventions in NCT01897116: Hydroxychloroquine (HCQ), Vemurafenib (VEM).

Is NCT01897116 still recruiting?

NCT01897116 is currently completed. Last updated 28 May 2020.

Last reviewed 2020-05-28 · How we verify

NCT01897116

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

Completed Phase 1 Last updated 28 May 2020

What this trial tests

Phase 1 trial testing Hydroxychloroquine (HCQ) in Melanoma in 8 participants. Completed in 5 October 2016.

Timeline

1 June 2013

Primary endpoint
12 July 2016

5 October 2016

Quick facts

Lead sponsor	Abramson Cancer Center at Penn Medicine
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	single
Primary purpose	treatment
Enrollment	8
Start date	1 June 2013
Primary completion	12 July 2016
Estimated completion	5 October 2016
Sites	1 location across United States

Drugs / interventions tested

Hydroxychloroquine (HCQ) — full drug profile →
Vemurafenib (VEM) — full drug profile →

Conditions studied

Melanoma — all drugs for Melanoma →

Sponsor

Abramson Cancer Center at Penn Medicine — full company profile →

Who can join

18 and older, any sex, with Melanoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of Adverse Events
Time frame: 8 weeks

Sponsor's own description

This is a Phase I study combining vemurafenib and hydroxychloroquine in the treatment of BRAF V600E+ metastatic melanoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting autophagy in cancer.
Levy JMM, Towers CG, Thorburn A. · · 2017 · cited 2029× · PMID 28751651 · DOI 10.1038/nrc.2017.53
Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.
Ma XH, Piao SF, Dey S, McAfee Q, et al · · 2014 · cited 377× · PMID 24569374 · DOI 10.1172/jci70454
Emerging strategies to effectively target autophagy in cancer.
Rebecca VW, Amaravadi RK. · · 2016 · cited 209× · PMID 25893285 · DOI 10.1038/onc.2015.99
Repurposing Drugs in Oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents.
Verbaanderd C, Maes H, Schaaf MB, Sukhatme VP, et al · · 2017 · cited 198× · PMID 29225688 · DOI 10.3332/ecancer.2017.781
Pathways and therapeutic targets in melanoma.
Shtivelman E, Davies MQ, Hwu P, Yang J, et al · · 2014 · cited 163× · PMID 24743024 · DOI 10.18632/oncotarget.1892
Chloroquine and hydroxychloroquine for cancer therapy.
Manic G, Obrist F, Kroemer G, Vitale I, et al · · 2014 · cited 150× · PMID 27308318 · DOI 10.4161/mco.29911
Tumor suppression and promotion by autophagy.
Ávalos Y, Canales J, Bravo-Sagua R, Criollo A, et al · · 2014 · cited 141× · PMID 25328887 · DOI 10.1155/2014/603980
Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma.
Spagnolo F, Ghiorzo P, Queirolo P. · · 2014 · cited 92× · PMID 25344914 · DOI 10.18632/oncotarget.2602

Verify or expand the search:

Other trials of Hydroxychloroquine (HCQ)

Trials testing the same drug.

NCT06862284 — Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome · Phase 2 · not yet recruiting
NCT04858633 — Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19 · Phase 3 · unknown
NCT04358068 — Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID · Phase 2 · terminated
NCT04349228 — Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals · Phase 3 · withdrawn
NCT04369742 — Treating COVID-19 With Hydroxychloroquine (TEACH) · Phase 2 · terminated

Other recruiting trials for Melanoma

Currently open trials in the same condition.

NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07224425 — A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it · Phase 1 · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT07225036 — Promoting Immunotherapy Efficacy With Low-Dose Liver RT · NA · recruiting
NCT07379138 — Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improve · NA · recruiting

Other Abramson Cancer Center at Penn Medicine trials

Trials by the same sponsor.

NCT07478848 — Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas · Phase 1 · not yet recruiting
NCT07059611 — Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
NCT07454499 — Engaging M-health for Symptom Monitoring and Health Promotion for Women on Endocrine Therapy for Breast Cancer (EmSHAPE) · NA · not yet recruiting
NCT07222241 — Comparing Numbing Techniques in Mohs Micrographic Surgery · NA · recruiting
NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01897116 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Abramson Cancer Center at Penn Medicine
Last refreshed: 28 May 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01897116.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing